Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 94Neoplasm Metastasis 6Breast Diseases 3Prostatic Neoplasms 2Ovarian Neoplasms 2Endometrial Neoplasms 2Breast Cancer Metastatic 2Triple Negative Breast Neoplasms 1Recurrence 1Primary Breast Cancer ER+ve 1Pancreatic Neoplasms 1Neoplasms 1Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer 1Multiple Endocrine Neoplasia Type 1 1Metastatic Beast Cancer 1Mammary Neoplasms, Animal 1Locoregional Recurrence 1Lethal Congenital Contracture Syndrome 2 1Hyperglycemia 1Hormone Receptor Positive Malignant Neoplasm of Breast 1HER2-positive Breast Cancer 1Granulosa cell tumor of the ovary 1Estrogen-receptor Positive Invasive Metastatic Breast Cancer 1Endometrial Stromal Tumors 1Endometrial Hyperplasia 1ER+ Breast Cancer 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Ductal 1Bulbo-Spinal Atrophy, X-Linked 1

Interventions

zenocutuzumab 2exemestane 1Vinorelbine 1Trastuzumab 1Letrozole 1Fulvestrant 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lethal Congenital Contracture Syndrome 2 × exemestane × Clear all
NCT03321981 2024-03-07

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Merus B.V.

Phase 2 Completed
105 enrolled 23 charts

Lethal Congenital Contracture Syndrome 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡